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The use of DNA as a drug was first proposed with the advent of 
molecular biology.[1,2] Advances in our understanding of the genetic 
basis of disease, coupled with progress in manipulating DNA, 
gave rise to the concept of genetic modification of an organism to 
correct a diseased state. Monogenic disorders offered convenient 
model systems to test this concept, as pathologies can be ascribed to 
abnormalities of single genes and replacement of aberrant genes with 
functional ones would, theoretically, reverse the pathology. As early 
as the 1970s, researchers explored ways of introducing DNA into cells 
to produce a therapeutic effect.[1,3] The first trial to evaluate genetic 
modification in humans employed the Shope papillomavirus (SPV) 
to correct hyperargininaemia, an inherited disorder that results from 
arginase deficiencies. SPV was thought to carry a copy of the arginase 
gene and it was proposed that infection with this virus would restore 
activity of the enzyme and reduce plasma arginine levels.[3] The virus 
was produced in large quantities, purified and administered to three 
siblings with hyperargininaemia. The trial proved unsuccessful, 
which the authors attributed to degeneration of the virus. However, 
subsequent research showed that SPV does not carry an arginase 
gene.[4] Although the trial yielded less-than-desirable results, the 
potential of using a virus as a vector for the delivery of therapeutic 
genes to cells was a revolutionary concept.
Emergence of recombinant DNA technology marked a turning 
point in the field of gene therapy. The ability to isolate and copy 
genes presented the way forward to produce functional copies 
of genes that are required for replacement therapy. This was the 
approach of the first approved human trial that evaluated delivery 
of a therapeutic gene.[5] The study aimed to correct severe combined 
immunodeficiency (SCID) resulting from a mutation of the gene 
encoding the adenosine deaminase (ADA) enzyme. Blaese et al.[5] 
cloned a functional copy of the ADA gene and inserted it into a 
replication-defective retrovirus using recombinant DNA technology. 
T cells were harvested from two patients with ADA-SCID, transduced 
with the recombinant virus and reinfused into the patients. The trial 
was carried out in 1990 and was hailed a success owing to the positive 
response seen in one of the two recipients. However, the field suffered 
a considerable setback in 1999, when a patient, Jesse Gelsinger, died 
after receiving gene replacement therapy in an efficacy trial aimed at 
restoring ornithine transcarbamylase deficiency.[6]
Since these initial exploratory studies, the field has grown to 
encompass a variety of therapeutic modalities that extend beyond 
gene replacement therapy for monogenic disorders. An advantage 
of gene therapy drugs is that their design is centred on rational 
principles. The genomics era has granted researchers unprecedented 
insight into the genetics underlying disease, and with the use of 
easy-to-understand principles it is possible to rationally design gene 
therapies to correct disease at a molecular level. In the modern era, 
gene therapy can be defined as the use of any nucleic acid sequence – 
either DNA or RNA – to produce a therapeutic effect, and therefore 
takes many forms. It may entail the use of a gene that undergoes 
transcription and translation to produce a therapeutic RNA or 
protein. Alternatively, the nucleic acid sequence itself may carry out 
the therapeutic function by binding (e.g. aptamers) or modifying 
(e.g. DNAzymes or ribozymes) disease targets. 
Gene therapy drugs typically comprise the therapeutic nucleic 
acid sequence contained within a delivery vector (Fig. 1). However, 
gene therapy has also given rise to cell therapy, which deals with the 
transfer of intact therapeutic cells to patients. This typically entails 
using technologies of gene therapy to engineer cells that confer some 
therapeutic characteristic. Advances in the fields of molecular biology, 
genetics and microbiology, among others, have driven progress in 
gene and cell therapy, and have facilitated the development of safer 
and increasingly efficacious therapeutics. The rapid development in 
the field is highlighted by the large number of clinical trials underway 
worldwide[7] and the recent approval of four gene-based therapeutics 
by the US Food and Drug Administration (FDA).[8] 
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To date, gene and cell therapy research in South Africa (SA) has 
been limited to laboratory-based experimental work and preclinical 
studies in mice. While there has not been a clinical trial initiated in 
the country, several haemophilia gene therapy programmes have 
been established in SA as an extension of existing international trials. 
On the continent as a whole, six gene therapy trials are currently 
underway or have received approval, but account for only 0.2% of the 
total number of trials worldwide.[7] 
The toolbox of strategies available to gene and cell therapy is 
continually expanding and currently includes gene replacement 
therapy, gene silencing and gene editing (Table 1). Discoveries in 
the biological sciences that have possible therapeutic application are 
rapidly being applied in the field of gene therapy. For example, RNA 
interference (RNAi) was being explored as a gene therapy approach 
soon after its discovery. The pathway uses RNA sequences called 
microRNAs to regulate gene expression. Artificial microRNAs can 
be designed to exploit this pathway and suppress any gene of interest 
and have been used extensively to silence pathology-causing genes 
or genes required for viral replication. Similarly, research in bacterial 
systems has revolutionised gene therapy and ushered in the era 
of genome editing. Transcription activator-like effector nucleases 
(TALENs) and the clustered regularly interspaced short palindromic 
repeats (CRISPR) and the CRISPR-associated (Cas) protein system 
are actively being assessed for their potential to disable viruses, 
correct genetic mutations or engineer cell therapies. 
SA and the rest of the continent suffer from a considerable disease 
burden, and while gene and cell therapy approaches may not be 
a panacea, they do offer novel avenues to be explored for treating 
intractable diseases such as HIV/AIDS.
Gene and cell therapy in South Africa
Concerning delivery
An important consideration for the use of gene therapy is the vector 
employed to deliver the therapeutic sequence to the intended site 
of action. Unlike small-molecule drugs, the large size and negative 
charge of nucleic acids make these molecules inherently refractory to 
crossing the negatively charged cell membrane. Viruses are naturally 
effective at delivering their genomes to host cells and are an obvious 
choice for delivery of therapeutic genes to tissues in vivo. To limit 
adverse effects related to the use of these vectors, they have been 
re-engineered by removing genes required for viral replication. 
Viral vectors are therefore replication defective and, while retaining 
their ability to infect cells and deliver their nucleic acid payload, are 
incapable of spreading. Recombinant viruses remain the vectors of 
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Fig. 1. Gene therapy technologies in the modern era. Gene therapies typically comprise the therapeutic sequence complexed with or incorporated into a vector 
for delivery. Delivery vectors are broadly divided into viral (A) and non-viral (B) vectors. Viruses are efficient at delivering their nucleic acid payload and are 
popular vectors for delivery of gene therapy. Recombinant viral vectors are produced by exploiting the virus’ natural assembly process. Typically, a recombinant 
viral genome that contains the therapeutic gene is expressed with viral structural and assembly components in a packaging cell line. The recombinant viral 
genome is subsequently assembled into the recombinant vector and can then be harvested and purified. As these vectors exploit the process of viral replication, 
the incorporated therapeutic sequences have to be a gene. In contrast, non-viral vectors can accommodate any nucleic acid sequence. Liposomes are the most 
common form of non-viral vector used in gene therapy applications and exploit the ability of lipids to form micelles in an aqueous environment. As these 
micelles share the same chemistry as the lipid bilayer of cells, they are able to fuse with it and so deliver their cargo into the cytoplasm. The use of cationic 
lipids in liposome formulation has proven to be ideal as it allows interaction not only with the negatively charged cell membrane but also with its negatively 
charged nucleic acid payload.
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choice for gene and cell therapy, accounting for 70% of all clinical 
trials.[7] 
Retroviral vectors were the first to be used and excellent successes 
were achieved in correcting SCID. However, concerns regarding the 
oncogenic potential of these viruses have led to a decline in their 
use. With lower oncogenic potential, lentiviruses are considered 
safer than other retroviruses and are still commonly used for gene 
therapy approaches. To date, adenoviruses have proven to be the 
most popular viral vector as they can accommodate large genes, 
are efficient delivery agents and achieve high levels of transgene 
expression. However, potent immune stimulation by adenoviruses 
is a major limitation of their use, as illustrated by the death of Jesse 
Gelsinger,[6] which has been attributed to a severe immune reaction 
to the recombinant adenovirus he received. In more recent years 
adeno-associated viruses (AAVs) have gained in popularity.[9,10] 
Although the AAV genome is relatively small, which limits the size of 
the therapeutic genes that these vectors can accommodate, AAVs are 
widely considered to be non-pathogenic and can infect a wide range 
of cell types at high efficiencies. More importantly, AAVs have been 
shown to express therapeutic sequences over the long term, a key 
consideration when developing gene therapy for chronic conditions.
The development of non-viral vectors (particularly cationic 
liposomes[11]) has offered an alternative to viral vectors for delivering 
therapeutic sequences. Non-viral vectors offer a number of 
advantages over viral vectors, which include: (i) an improved safety 
profile, as they are non-immunogenic; (ii) facile and inexpensive 
up-scale of manufacture compared with viral vectors, and (iii) 
the ability to accommodate any type of nucleic sequence and not 
only genes. However, the use of non-viral vectors involves unique 
challenges, which include optimising serum stability in vivo, targeted 
delivery to sites of disease and endosomal escape upon cell entry. 
The Non-Viral Gene Delivery Laboratory at the University of 
KwaZulu-Natal, SA, focuses on the development of cationic lipids 
for the formulation of hepatotropic liposomes. Using fundamental 
principles of biochemistry, this group has produced promising 
results with regard to the design of liposomes that exhibit enhanced 
stability, targeted delivery to liver-derived cells and escape from 
endolysosomal degradation.[12-14] This group has also evaluated the 
use of gold nanoparticles as synthetic vectors for the delivery of DNA 
drugs. The data from studies on cultured cells are promising and 
the technology offers value for clinical translation. Limitations of 
delivery vectors remain the most important hurdle to be overcome 
before widespread use of gene therapy becomes a clinical reality. 
However, continuous development of both viral and non-viral vectors 
is advancing the field to the point where clinical translation of gene 
therapy will be routine. 
Gene and cell therapy against HIV infection
The scourge of the HIV/AIDS pandemic has been exacerbated by 
none of the available interventions being able to cure the disease. 
However, gene or cell therapy offers hope in this respect. A distinction 
should be made between a sterilising cure and a functional cure. A 
sterilising cure results not only in an undetectable viral load but also 
in the elimination of the viral reservoir. The well-publicised case 
of Timothy Brown is the only reported case of a sterile cure.[6] In 
contrast, a functional cure would result in a reduced or absent viral 
load, but not in eliminating the viral reservoir. In this case, a reduced 
requirement for antiretroviral therapy and a less-compromised 
Table 1. Toolbox of gene and cell therapy strategies for indicated diseases
Disease type Gene therapy Cell therapy
Monogenic disorders (e.g. 
haemophilia A and B)
Gene replacement therapy
• Delivers a functional copy of the mutant gene to the target 
organ
• Licensed gene replacement therapies: Glybera, Strimvelis
Gene repair
• Repairs mutant gene in situ using gene-editing technologies 
(zinc finger nucleases, TALENs, CRISPR/Cas)
Not applicable
Cancer Suicide gene therapy
• Delivers suicide gene to the tumour
• Expression of suicide gene produces a toxic compound that 
kills the tumour
• Example: Imlygic
Anti-oncogene therapy
• Oncogene expression inhibited with therapeutic DNA or RNA 
sequences
• Example: RNA interference-mediated silencing
Tumour suppressor gene therapy
• Delivers tumour suppressor gene (p53) to tumour
• Example: Gendicine
Chimeric antigen receptor T cells
• T cells are modified to express a T cell 
receptor (TCR) targeted to specific 
tumour antigens
• Viral and non-viral vectors used to deliver 
TCR gene to T cells ex vivo
• Modified T cells transplanted into the 
patient
• Licensed therapies: Kymriah, Yescarta
Infectious diseases Gene silencing
• Viral genes silenced with therapeutic DNA or RNA
• Host genes required for viral replication silenced
• Example: Exploiting the RNA interference pathway to silence 
genes
Genome editing
• Viral genome disabled using gene-editing technologies
Ex vivo therapy
• Patient cells depleted of host-dependency 
factor ex vivo
• Resistant cell reinfused into the patient
• Potential of this strategy highlighted by 
the Berlin patient, Timothy Brown (HIV)
TALENs = transcription activator-like effector nucleases; CRISPR/Cas = clustered regularly interspaced short palindromic repeats/CRISPR-associated protein system.
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immune system could prove potentially beneficial, as it may result in 
fewer infections and better immune surveillance (and possibly also 
fewer cancers). The objective of the South African Medical Research 
Council (SAMRC) Extramural Unit for Stem Cell Research has been 
to identify and target host elements in order to render CD4+ T cells 
resistant to HIV.[15] This was achieved by targeting expression of 
C-C chemokine receptor type 5, a co-receptor for viral entry, using 
an artificial microRNA.[16] This gene-engineering approach was 
assessed in vivo in human immune system (HIS) mice infected with 
HIV as a preclinical proof of concept.[17] Work was also directed at 
optimising the ex vivo expansion of haematopoietic stem cells.[18] Key 
findings and expertise gained relate to: (i) efficient delivery of the 
lentiviral construct into haematopoietic stem and progenitor cells 
(HSPCs); (ii) demonstration of multilineage haematopoiesis from 
gene-engineered HSPCs, and (iii) functional cure of HIV when HIS 
mice were transplanted with gene-engineered HSPCs (preclinical 
proof of concept). The group is working towards initiating a phase I 
clinical trial based on the preclinical data.
Gene therapy for viral hepatitis
Infection with the hepatitis B virus (HBV) remains a serious 
medical problem, with ~257 million chronic patients worldwide.[19] 
Sub-Saharan Africa is a region of high endemicity, with a reported 
burden of 4.6 - 8.5%. Chronic infection is associated with cirrhosis 
and hepatocellular carcinoma, which together were responsible for 
~867 000 deaths worldwide in 2016. The limited benefit of available 
intervention strategies has led the Wits/SAMRC Antiviral Gene 
Therapy Research Unit (AGTRU) to explore gene therapy against 
chronic HBV infection. The group has a well-established workflow, 
from basic development to taking therapeutics to preclinical testing 
in animal models. Leveraging its expertise in molecular biology, the 
unit has been able to capitalise on developments in gene therapy 
to create novel antiviral therapeutics. The AGTRU has published 
extensively on RNA-based therapeutics, including ribozymes, small 
interfering RNAs and artificial microRNAs.[20-22] More recently the 
unit has been exploring the use of TALENs[23] and the CRISPR/Cas 
system[10] for targeted mutation of HBV DNA, which disables the 
virus. While this approach does not achieve a sterilising cure, it is able 
to produce a functional cure for hepatitis B, a previously undreamt 
of goal in anti-HBV therapeutics. The unit has also explored the use 
of recombinant adenoviruses,[24] lentiviruses[25] and AAVs,[9,10] given 
its core competency in viral vectorology. Considerable progress has 
been made and a number of candidates have been identified for 
further development. Current research efforts are directed at clinical 
translation.
Haemophilia gene therapy 
Haemophilia A and B are X-linked monogenic disorders 
caused by deficiencies in coagulation factor VIII (FVIII) and IX 
(FIX), respectively.[26] The epidemiology and natural history of 
haemophilia are mirrored in all nations and geographic regions of 
the world, including developing countries, where haemophilia is 
grossly underdiagnosed and poorly managed. Deficiency of FVIII 
or FIX presents with spontaneous or trauma-induced bleeding, 
predominantly into joints, with consequent crippling and debilitating 
arthropathies.[27] The lifelong risk of haemophilia bleeding is 
associated with high mortality and significant morbidity. The current 
standard of care for haemophilia uses plasma-derived or recombinant 
products that replace the missing factor. There are several challenges 
associated with replacement therapy, including patients’ developing 
antibodies against the replacement proteins and the increased 
treatment burden associated with regular intravenous infusion of 
clotting factors.[28] Inhibitors of replacement therapy are found in 
up to 30% of patients and result in poor quality of life, increased 
mortality and morbidity and generally poor treatment outcomes.[29] 
Gene therapy for haemophilia offers a single administration of the 
therapeutic to potentially produce a lifelong cure and so overcomes 
many of the shortcomings of traditional replacement therapy. Several 
gene therapy programmes for both haemophilia A and B are ongoing 
and use hepatotropic AAVs to deliver the factor-encoding transgene 
to the liver.[30-32] The results of both FVIII and FIX gene therapy have 
been encouraging, with many patients successfully converted from 
severe to moderate or mild phenotypes. At 8-year follow-up, there 
has been no loss of transgene expression or adverse events in the 
FIX gene therapy studies. Continued follow-up will help to establish 
whether expression will be lifelong. 
Experience of haemophilia gene therapy in SA is increasing, with 
several FVIII and FIX programmes having started. Two SA patients 
who received gene therapy for severe haemophilia B in Europe 
are currently being followed up locally. Their FIX expression has 
remained stable in the absence of replacement therapy. A regional 
gene therapy infusion centre has been set up in Johannesburg, SA, 
and patients for several FVIII and FIX gene therapy studies are 
currently being recruited. Participation of patients of African origin 
in gene therapy is particularly important, as they have generally been 
underrepresented in global gene therapy studies. Eligibility for these 
studies requires the absence of antibodies against the viral vector 
used to deliver the gene therapy. Characterisation of the prevalence 
of antibodies against various AAV serotypes in Africa is currently 
underway. With high levels of poverty, inequality and a high 
disease burden, Africa will undoubtedly benefit from haemophilia 
gene therapy, as replacement therapy is currently unaffordable and 
inaccessible to the majority of patients in the region.
Conclusion
The question is often raised as to whether investment in technologies 
such as gene therapy is relevant to lower-to-middle income countries 
(LMICs). Basic healthcare, education and food and water security 
are usually considered more pressing priorities. In other words, can 
investment in sophisticated technologies be justified in the face of an 
inability to meet basic needs? Our view is that the need in LMICs is 
as great, if not greater, as in high-income countries, where most of the 
research on gene therapy is performed.[7] This opinion is based largely 
on the promising expected clinical outcomes and principles of health 
economics. Little has been done to estimate the benefits to LMICs that 
would accrue from large-scale exploitation of new technologies arising 
from developments of the genomics era (including gene therapy). For 
example, the cost of living with HIV needs to be assessed against that 
of a possibly expensive single therapeutic procedure. Administering 
lifelong antiretroviral therapy, treatment of complicating infections 
and cancer, and the financial consequences that result from illness 
of economically active individuals collectively place a high burden 
on society. Administering one-off curative therapeutic procedures, 
such as those which may be possible with gene therapy, is therefore 
attractive. Although estimated costs of gene therapy are high, bringing 
this technology into mainstream practice is likely to reduce costs as 
economies of scale come to bear. In addition to investment in these 
technologies, our country also needs to develop the requisite regulatory 
and legislative frameworks to manage gene and cell therapeutics that 
will eventually enter the SA market.[33,34]
Significant progress in gene and cell therapy has been made over 
the past few decades, with a substantial increase in the number of 
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studies that have progressed to clinical trials. This has translated to 
a number of therapeutics entering the market, with the first such 
drug, Gendicine, having been licensed in China for the treatment 
of head and neck tumours since 2003. Glybera and Strimvelis 
were approved by the European Medicines Agency in 2012 and 
2016, respectively. Since 2015, the FDA has approved licenses for 
four gene-based therapeutics (Imlygic, Kymriah, Luxturna and 
Yescarta), with Kymriah and Yescarta also having been approved for 
commercialisation in Europe. It is clear that gene and cell therapy 
holds significant promise to address unmet medical needs. Advances 
in the field will soon see gene therapy taking its place at the forefront 
of medical science. It is important that SA takes the necessary steps 
to reap the benefits of these promising technologies.
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